• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

COVID-19 Treatment RCT Results: Combination Interferon beta-1b, Lopinavir-Ritonavir and Ribavirin

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • There are multiple trials underway to determine efficacy of various treatments for COVID-19
    • Lopinavir/ritonavir is a combination HIV protease inhibitor medication
    • Ribavirin is a nucleoside analogue
  • Hung et al. (Lancet, 2020) sought to determine the efficacy and safety of adding interferon beta-1b to lopinavir–ritonavir, and ribavirin for the treatment of COVID-19

METHODS:

  • Multicenter, prospective, open-label randomized phase 2 controlled trial (RCT)
    • 6 Hong Kong hospitals | Between February 10 and March 20, 2020
  • Participants
    • Hospitalized
    • Confirmed COVID-19
  • Study design
    • Randomization (2:1) for a 14 day course of the following
      • Combination group: Combination of lopinavir 400 mg and ritonavir 100 mg every 12 hours | Ribavirin 400 mg every 12 hours | 3 doses of 8 million IU of interferon beta-1b on alternate days
      • Control group: Lopinavir 400 mg and ritonavir 100 mg every 12 h (control group)
  • Primary outcome
    • Time for nasopharyngeal swab to be negative for SARS-CoV-2 (using RT-PCR)

RESULTS:

  • 127 patients were recruited
    • Combination group: 86
    • Control group: 41
  • Median time to symptom onset to start of study treatment: 5 days (IQR 3–7)
  • Combination group had a shorter time from treatment to negative swab result (p=0·0010)
    • Combination group: 7 days
    • Control group: 12 days
    • Hazard ratio (HR): 4·37 (95% CI, 1·86–10·24)
  • Adverse events
    • No difference between groups
    • Main side effects included limited nausea and diarrhea | Discontinuation of lopinavir–ritonavir in one patient (control group) because of biochemical hepatitis
    • No deaths in either group

CONCLUSION:

  • In this phase 2 study, the authors conclude that

…early triple antiviral therapy was safe and superior to lopinavir–ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19

  • Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted

Learn More – Primary Sources:

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Remdesivir Emergency Authorization: FDA Update and Summary of Preliminary NIH Study Data
NIH COVID-19 Treatment Guidelines
ARDS, Critical Care and COVID-19: ‘Surviving Sepsis Campaign’ Guidelines and Key Points

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site